Clinical Study Results
Research Sponsor: AstraZeneca AB
Drugs Studied: Tremelimumab
Study Title: A study to learn how tremelimumab works in participants with
advanced solid tumors
Thank you!
Thank you to the participants who took part in the clinical study for the study drug
tremelimumab. All of the participants helped researchers learn more about tremelimumab to
help people with advanced cancer.
AstraZeneca AB sponsored this study and thinks it is important to share the results
of the study with you and the public. An independent non-profit organization called
CISCRP helped prepare this summary of the study results for you. We hope it helps
you understand and feel proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak with
the doctor or staff at your study site.
What is happening with the study now?
The participants could be in the study for up to 36 months, but the entire study took
about 30 months to finish. The study started in November 2015 and ended in
February 2018.
The study included 64 participants in 5 countries: Belgium, the Netherlands, Poland,
South Korea, and the United States.
The sponsor, AstraZeneca AB, reviewed the data collected when the study ended and
created a report of the results. This is a summary of that report.
1